Immunic (NASDAQ:IMUX) is up 8% after receiving FDA allowance to initiate its phase 2, CALVID-1 clinical trial of IMU-838, an oral, selective dihydroorotate dehydrogenase inhibitor, in COVID-19 at centers in U.S.
Top-line data are expected later this year.
https://seekingalpha.com/news/3581460-immunic-launches-mid-stage-imuminus-838-trial-in-covidminus-19
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.